MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer

Standard-of-care for resectable gastric/gastroesophageal junction cancer includes surgery and neoadjuvant-adjuvant 5-fluorouracil-leucovorin-oxaliplatin-docetaxel (FLOT) chemotherapy. Early-phase clinical studies support further clinical development of the immune checkpoint inhibitor (ICI); durvalum...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Future oncology (London, England) Ročník 18; číslo 20; s. 2465
Hlavní autori:	Janjigian, Yelena Y, Van Cutsem, Eric, Muro, Kei, Wainberg, Zev, Al-Batran, Salah-Eddin, Hyung, Woo Jin, Molena, Daniela, Marcovitz, Michelle, Ruscica, Dario, Robbins, Scott H, Negro, Alejandra, Tabernero, Josep
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England 01.06.2022
Predmet:	Adenocarcinoma - pathology Antibodies, Monoclonal Antineoplastic Combined Chemotherapy Protocols - adverse effects Clinical Trials, Phase III as Topic Esophagogastric Junction - pathology Fluorouracil - adverse effects Humans Neoadjuvant Therapy Randomized Controlled Trials as Topic Stomach Neoplasms - pathology neoadjuvant-adjuvant resectable durvalumab gastric cancer immunotherapy PD-L1 gastroesophageal junction cancer immune checkpoint inhibitors chemotherapy
ISSN:	1744-8301, 1744-8301
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!